Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Michael B Hovater & Edgar A Jaimes. (2013) Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination. Integrated Blood Pressure Control 6, pages 59-67.
Read now
Read now
Giuseppe Mancia, Robert Fagard, Krzysztof Narkiewicz, Josep Redon, Alberto Zanchetti, Michael Böhm, Thierry Christiaens, Renata Cifkova, Guy De Backer, Anna Dominiczak, Maurizio Galderisi, Diederick E. Grobbee, Tiny Jaarsma, Paulus Kirchhof, Sverre E. Kjeldsen, Stéphane Laurent, Athanasios J. Manolis, Peter M. Nilsson, Luis Miguel Ruilope, Roland E. Schmieder, Per Anton Sirnes, Peter Sleight, Margus Viigimaa, Bernard Waeber & Faiez Zannad. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure 22:4, pages 193-278.
Read now
Read now
Yonghong Huan & Raymond Townsend. (2012) The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. Expert Opinion on Pharmacotherapy 13:16, pages 2409-2415.
Read now
Read now
Fabio Angeli, Gianpaolo Reboldi, Giovanni Mazzotta, Cristina Poltronieri & Paolo Verdecchia. (2012) Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. Expert Opinion on Drug Safety 11:4, pages 659-670.
Read now
Read now
Eric Judd & Edgar A Jaimes. (2012) Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. Expert Review of Cardiovascular Therapy 10:3, pages 293-303.
Read now
Read now
Hernán Trimarchi. (2011) Role of aliskiren in blood pressure control and renoprotection. International Journal of Nephrology and Renovascular Disease 4, pages 41-48.
Read now
Read now
Roberto Fogari, Annalisa Zoppi, Amedeo Mugellini, Pamela Maffioli, Pierangelo Lazzari, Claudio Monti & Giuseppe Derosa. (2011) Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. Expert Opinion on Pharmacotherapy 12:9, pages 1351-1358.
Read now
Read now
Adrienne S Zion & Joseph L Izzo. (2011) Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results. Expert Review of Cardiovascular Therapy 9:4, pages 421-427.
Read now
Read now
Roberto Fogari & Annalisa Zoppi. (2010) New class of agents for treatment of hypertension: focus on direct renin inhibition. Vascular Health and Risk Management 6, pages 869-882.
Read now
Read now
Alberto F Rubio-Guerra, David Castro-Serna, Cesar I Elizalde Barrera & Luz M Ramos-Brizuela. (2009) Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors. Integrated Blood Pressure Control 2, pages 55-62.
Read now
Read now
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J. Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Antony Heagerty, Sverre E. Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H. Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E. Schmieder, Harry A.J. Struijker-Boudier, Pieter A. Van Zwieten, Margus Viigimaa & Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure 18:6, pages 308-347.
Read now
Read now
Articles from other publishers (37)
Jiantong Shen, Wenming Feng, Yike Wang, Qiyuan Zhao, Billong Laura Flavorta & Jingya Lu. (2021) Efficacy and safety of aliskiren combination therapy: a protocol for an umbrella review. BMJ Open 11:3, pages e043807.
Crossref
Crossref
Nikolaos-Dimitrios Pantzaris, Evangelos Karanikolas, Konstantinos Tsiotsios & Dimitrios Velissaris. (2017) Renin Inhibition with Aliskiren: A Decade of Clinical Experience. Journal of Clinical Medicine 6:6, pages 61.
Crossref
Crossref
Demetrius Ellis & Yosuke Miyashita. 2016. Pediatric Nephrology. Pediatric Nephrology
2023
2097
.
S Friedrich, U Zeymer, R Dechend, I Hagedorn, T Riemer, C Zemmrich, P Bramlage, D Pittrow, J Senges & R E Schmieder. (2014) The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry. Journal of Human Hypertension 29:5, pages 316-323.
Crossref
Crossref
Walid M. Ebeid, Ehab F. Elkady, Asmaa A. El-Zaher, Ramzia I. El-Bagary & Gabor Patonay. (2014) Steady-state and synchronous spectrofluorimetric methods for simultaneous determination of aliskiren hemifumarate and amlodipine besylate in dosage forms. Luminescence 29:7, pages 878-883.
Crossref
Crossref
Gregg Lanier, Kedar Sankholkar & Wilbert S. Aronow. (2014) Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin–Angiotensin–Aldosterone System Antagonists. American Journal of Therapeutics 21:5, pages 419-435.
Crossref
Crossref
Demetrius Ellis & Yosuke Miyashita. 2014. Pediatric Nephrology. Pediatric Nephrology
1
87
.
Yukai Liu, Ken Chen, Xun Kou, Yu Han, Lin Zhou & Chunyu Zeng. (2013) Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-Analysis of Randomized Controlled Trials. PLoS ONE 8:7, pages e70111.
Crossref
Crossref
. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal 34:28, pages 2159-2219.
Crossref
Crossref
Giuseppe Mancia, Robert Fagard, Krzysztof Narkiewicz, Josep Redón, Alberto Zanchetti, Michael Böhm, Thierry Christiaens, Renata Cifkova, Guy De Backer, Anna Dominiczak, Maurizio Galderisi, Diederick E. Grobbee, Tiny Jaarsma, Paulus Kirchhof, Sverre E. Kjeldsen, Stéphane Laurent, Athanasios J. Manolis, Peter M. Nilsson, Luis Miguel Ruilope, Roland E. Schmieder, Per Anton Sirnes, Peter Sleight, Margus Viigimaa, Bernard Waeber & Faiez Zannad. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension 31:7, pages 1281-1357.
Crossref
Crossref
T W LittlejohnIIIIII, S W Jones, J Zhang, H Hsu & D L Keefe. (2012) Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. Journal of Human Hypertension 27:5, pages 321-327.
Crossref
Crossref
Michel Azizi & Joël Ménard. (2012) Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?. Cardiovascular Drugs and Therapy 27:2, pages 145-153.
Crossref
Crossref
Alexander V. Murray, Wolfgang Koenig, Juan Garcia‐Puig, Samir Patel, Alkaz Uddin PhD & Jack Zhang. (2012) Safety and Efficacy of Aliskiren/Amlodipine/Hydrochlorothiazide Triple Combination in Patients With Moderate to Severe Hypertension: A 54‐Week, Open‐Label Study. The Journal of Clinical Hypertension 14:12, pages 821-827.
Crossref
Crossref
Yves Lacourcière, Stefano Taddei, George Konis, Hui Fang, Thomas Severin & Jack Zhang. (2012) Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension. Journal of Hypertension 30:10, pages 2047-2055.
Crossref
Crossref
R. C. Braun-Dullaeus, S. B. Shustov, C. Alvarez, G. G. Rogelio, J. Zhang, S. Hristoskova & D. A. Häring. (2012) Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial. International Journal of Clinical Practice 66:9, pages 834-842.
Crossref
Crossref
Gowraganahalli Jagadeesh, Pitchai Balakumar & Norman Stockbridge. (2012) How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?. Cellular Signalling 24:8, pages 1583-1591.
Crossref
Crossref
Ludovit Paulis, Ulrike M. Steckelings & Thomas Unger. (2012) Key advances in antihypertensive treatment. Nature Reviews Cardiology 9:5, pages 276-285.
Crossref
Crossref
Keith C. Ferdinand, Richard Weitzman, Das Purkayastha, Kanaka Sridharan & Edgar A. Jaimes. (2012) Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with Stage 2 hypertension. Journal of the American Society of Hypertension 6:3, pages 219-227.
Crossref
Crossref
Matthew R. Weir, Donna S. Hanes & David K. Klassen. 2012. Brenner and Rector's The Kidney. Brenner and Rector's The Kidney
1824
1878
.
Julian Segura, Cesar Cerezo, Jose A. Garcia-Donaire, Roland E. Schmieder, Manuel Praga, Alejandro de la Sierra & Luis M. Ruilope. (2011) Validation of a therapeutic scheme for the treatment of resistant hypertension. Journal of the American Society of Hypertension 5:6, pages 498-504.
Crossref
Crossref
Myron H. Weinberger, Joseph L. IzzoJr.Jr., Das Purkayastha, Richard Weitzman & Henry R. Black. (2011) Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. Journal of the American Society of Hypertension.
Crossref
Crossref
Yu. V. Zhernakova, V. B. Mychka, Yu. A. Ponomarev, S. N. Tolstov, E. V. Tishina, K. P. Ivanov & I. E. Chazova. (2011) Direct renin inhibitor aliskiren in women with menopausal metabolic syndrome and arterial hypertension. Cardiovascular Therapy and Prevention 10:4, pages 33-38.
Crossref
Crossref
Henry R. Black, Myron H. Weinberger, Das Purkayastha, Joleen Lee, Kanaka Sridharan, Marc Israel, Robert Hilkert & Joseph Izzo. (2011) Comparative Efficacy and Safety of Combination Aliskiren/Amlodipine and Amlodipine Monotherapy in African Americans With Stage 2 Hypertension. The Journal of Clinical Hypertension 13:8, pages 571-581.
Crossref
Crossref
William B. White, Robert Bresalier, Allen P. Kaplan, Biff F. Palmer, Robert H. Riddell, Anastasia Lesogor, William Chang & Deborah L. Keefe. (2011) Safety and Tolerability of the Direct Renin Inhibitor Aliskiren in Combination With Angiotensin Receptor Blockers and Thiazide Diuretics: A Pooled Analysis of Clinical Experience of 12,942 Patients. The Journal of Clinical Hypertension 13:7, pages 506-516.
Crossref
Crossref
Joseph L. Izzo & Adrienne S. Zion. (2011) Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues. Therapeutic Advances in Cardiovascular Disease 5:3, pages 169-178.
Crossref
Crossref
Natale Daniele BrunettiLuisa De GennaroPier Luigi PellegrinoAndrea CuculoLuigi ZiccardiAntonio GaglioneMatteo Di Biase. (2011) Direct renin inhibition: update on clinical investigations with aliskiren. European Journal of Cardiovascular Prevention & Rehabilitation 18:3, pages 424-437.
Crossref
Crossref
M. Azizi, M. Frank, O. Steichen & A. Blanchard. (2011) Intérêts et limites de l’inhibition de la rénine par l’aliskiren. Annales Pharmaceutiques Françaises 69:3, pages 142-150.
Crossref
Crossref
Keith C. Ferdinand, Richard Weitzman, Marc Israel, Joleen Lee, Das Purkayastha & Edgar A. Jaimes. (2011) Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. Journal of the American Society of Hypertension 5:2, pages 102-113.
Crossref
Crossref
Graziano Riccioni. (2011) Aliskiren in the Treatment of Hypertension and Organ Damage. Cardiovascular Therapeutics 29:1, pages 77-87.
Crossref
Crossref
Muzaffar Iqbal. (2011) Clinical Perspective on the Management of Hypertension. Indian Journal of Clinical Medicine 2, pages IJCM.S5475.
Crossref
Crossref
Vivencio Barrios & Carlos Escobar. (2010) Aliskiren in the Management of Hypertension. American Journal Cardiovascular Drugs 10:6, pages 349-358.
Crossref
Crossref
Sean T. Duggan, Claudine M. Chwieduk & Monique P. Curran. (2010) Aliskiren. Drugs 70:15, pages 2011-2049.
Crossref
Crossref
William B. White, Robert Bresalier, Allen P. Kaplan, Biff F. Palmer, Robert H. Riddell, Anastasia Lesogor, William Chang & Deborah L. Keefe. (2010) Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension. The Journal of Clinical Hypertension 12:10, pages 765-775.
Crossref
Crossref
M. Azizi. (2010) Les nouvelles modalités d’inhibition du système rénine angiotensine : les inhibiteurs de la rénine et l’immunisation active contre l’angiotensine II. La Revue de Médecine Interne 31:10, pages 659-664.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:12.
Crossref
Crossref
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Anthony Heagerty, Sverre E Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E Schmieder, Harry AJ Struijker-Boudier, Pieter A van Zwieten, Margus Viigimaa & Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 27:11, pages 2121-2158.
Crossref
Crossref
C Venkata S Ram. (2009) Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiology 5:5, pages 453-465.
Crossref
Crossref